
Genomate Health is a precision oncology company that offers Genomate®, a computational intelligence-powered clinical decision support system. This system helps oncologists identify the most effective targeted therapies for cancer patients by analyzing individual tumor molecular profiles. Unlike traditional methods, Genomate® leverages AI to predict treatment responses with high accuracy, providing data-backed reports to guide personalized treatment decisions. The company has demonstrated significant improvements in median progression-free survival (mPFS) and positive response rates for patients using Genomate-recommended treatments. Genomate Health partners with healthcare organizations, including oncologists, biopharma companies, payers, and cancer centers, to advance personalized medicine.

Genomate Health is a precision oncology company that offers Genomate®, a computational intelligence-powered clinical decision support system. This system helps oncologists identify the most effective targeted therapies for cancer patients by analyzing individual tumor molecular profiles. Unlike traditional methods, Genomate® leverages AI to predict treatment responses with high accuracy, providing data-backed reports to guide personalized treatment decisions. The company has demonstrated significant improvements in median progression-free survival (mPFS) and positive response rates for patients using Genomate-recommended treatments. Genomate Health partners with healthcare organizations, including oncologists, biopharma companies, payers, and cancer centers, to advance personalized medicine.
Headquarters & founding: Cambridge, MA; founded 2022 (spin-out of Oncompass Medicine)
Product: Genomate® — AI-powered clinical decision support platform for precision oncology
Clinical impact: Reports claim improved median progression-free survival and higher response rates for Genomate-recommended treatments
Recent funding: Raised $2.25M in Apr 2024; additional $2M announced May 2025
Precision oncology; clinical decision support for cancer treatment selection
2022
Biotechnology
5729007
Reported on Crunchbase
2250000
Company announcement of $2.25M raise to develop computational model and pursue FDA clearance
2000000
Company announcement of additional $2M investment to support U.S. entry
“STR T Holding Nyrt; confidential and individual investors (e.g., Dr. Gyözö János Drozdy) listed in public profiles”
| Company |
|---|